39  4.06 (11.62%)		07-29 16:00
Open: 35.14 High: 39.26 Volume: 706,232		Pre. Close: 34.94 Low: 35.14 Market Cap: 1,118(M)

Short term
Mid term
Targets	6-month :	45.83	1-year :	53.53
Resists	First :	39.24	Second :	45.83
Pivot price	33.5
Supports	First :	33.13	Second :	29.36
MAs	MA(5) :	35.66	MA(20) :	33.48
	MA(100) :	29.28	MA(250) :	0
MACD	MACD :	1.3	Signal :	0.9
%K %D	K(14,3) :	77.5	D(3) :	74.5
RSI	RSI(14): 72.7
52-week	High :	39.24	Low :	13.35

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LBRX ] has closed It is unclear right now based on current values. 73.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	39.29 - 39.45	39.45 - 39.6
Low:	34.78 - 34.94	34.94 - 35.09
Close:	38.72 - 38.99	38.99 - 39.26

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Wed, 29 Jul 2026
LB Pharmaceuticals Secures $150 Million via Private Placement to Advance LB-102 Pipeline Expansion - kalkinemedia.com

Wed, 29 Jul 2026
LB Pharmaceuticals Announces $150 Million Private Placement - The Manila Times

Wed, 29 Jul 2026
LB Pharmaceuticals Prices ~$150 Million Private Placement of Stock and Pre-Funded Warrants - TradingView

Wed, 29 Jul 2026
LB Pharmaceuticals Plans $150M Raise for LB-102 Expansion - Stock Titan

Mon, 27 Jul 2026
LB Pharmaceuticals Inc (LBRX) Cash Flow - tradingkey.com

Sat, 11 Jul 2026
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	29 (M)
Shares Float	18 (M)
Held by Insiders	0.2 (%)
Held by Institutions	107.1 (%)
Shares Short	4,260 (K)
Shares Short P.Month	4,300 (K)

EPS	-1.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	13.21
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	-19.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.57
Qtrly Earnings Growth	0 %
Operating Cash Flow	-50 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-28.68
PEG Ratio	0
Price to Book value	2.95
Price to Sales	0
Price to Cash Flow	-22.21

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.